CLL
News
In newly diagnosed CLL, mutation tests are advised
News
FDA approves venetoclax for CLL with 17p deletion
News
Feds advance cancer moonshot with expert panel, outline of goals
Possible opportunities include vaccine development, early-detection technology, single-cell genomic analysis, immunotherapy, a focus on pediatric...
News
RPS15 mutations prevalent in aggressive chronic lymphocytic leukemia
Key clinical point: Aberrations in the RPS15 gene before therapy may be an indicator of aggressive pathobiology in chronic lymphocytic leukemia....
News
Idelalisib use halted in six combo therapy trials, FDA announces
News
Ibrutinib approved as first-line therapy for all CLL patients
News
Venetoclax shows promise for relapsed CLL, SLL
Daily oral treatment with venetoclax induced substantial responses with manageable adverse effects in patients with relapsed chronic lymphocytic...
News
Acalabrutinib yields 95% overall response in relapsed CLL
Key clinical point: Acalabrutinib, a more selective and therefore less-toxic relative of ibrutinib, produced a high response rate and durable...